The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
HOME > BUSINESS
BUSINESS
- Mitsubishi Tanabe Wants to Make a Challenge in Experienced Field, President Says on Licensed Cell Therapy
December 9, 2016
- Nippon Kayaku Wins Reversal in Elplat Patent Suit
December 9, 2016
- Keytruda Launch Planned in Early Next Year: MSD Japan Chief
December 9, 2016
- Pfizer’s “Established” Pharma Business Expands to “Essential Health” to Include New Drugs, Copromoted Products
December 9, 2016
- Ethical Drug Sales Tumble 12.2% in October: Crecon Report
December 8, 2016
- Mitsubishi Tanabe Fending Off Inroads from Biosimilars through Add’l Indications for Remicade
December 8, 2016
- Heike Prinz to Become 1st Female President of Bayer Yakuhin
December 7, 2016
- Acquisition of Long-Listed Drugs to Promote Generic Sales; Sales Target of 50 Billion Yen “in Range”: Kyowa Pharm
December 7, 2016
- Chugai to Enter Hemophilia Field with Emicizumab; Peak Sales Could Top 200 Billion Yen
December 6, 2016
- Kaketsuken Wraps Up Blanket Re-Inspection, Says There’s No Quality or Safety Concern
December 6, 2016
- GSK Won’t Invest in Aspen Japan
December 6, 2016
- Toyama Chemical Begins Japan PIII for Macrolide Antibiotic
December 6, 2016
- AZ Japan to Shed 40 Primary Care Jobs Via Voluntary Redundancy
December 6, 2016
- Novartis Files Tafinlar-Mekinist Combo for NSCLC
December 6, 2016
- Daiichi Sankyo’s HER2-Targeting ADC Gets Fast-Track Status in US
December 5, 2016
- Takeda, Lightstone Ventures Set Up Neuroscience R&D Firm
December 5, 2016
- Shionogi’s Sakigake-Designated Flu Drug Delivers Add’l Favorable PII Data
December 5, 2016
- Annual Price Revision Could Plunge Pharma Industry into Doldrums: Pfizer Japan Chief
December 5, 2016
- FDA Accepts sNDA for Abilify Maintena’s Bipolar I Disorder Indication
December 2, 2016
- Novartis Seeks Aplastic Anemia Indication for Revolade, Neoral
December 2, 2016
ページ
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Novartis’ Pluvicto (lutetium vipivotide tetraxetan (177Lu)) won reimbursement listing in Japan in November as a radioligand therapy (RLT) for PSMA-positive…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…